Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1731825

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1731825

Inactivated Vaccines

PUBLISHED:
PAGES: 468 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Inactivated Vaccines Market to Reach US$54.1 Billion by 2030

The global market for Inactivated Vaccines estimated at US$41.6 Billion in the year 2024, is expected to reach US$54.1 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Viral Vaccine, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$35.3 Billion by the end of the analysis period. Growth in the Bacterial Vaccine segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.3 Billion While China is Forecast to Grow at 8.3% CAGR

The Inactivated Vaccines market in the U.S. is estimated at US$11.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Inactivated Vaccines Market - Key Trends & Drivers Summarized

How Do Inactivated Vaccines Maintain Their Relevance in a Rapidly Evolving Immunization Landscape?

Inactivated vaccines, which contain pathogens that have been killed through chemical or physical processes, continue to serve as a cornerstone of global immunization efforts due to their robust safety profile and broad applicability. Unlike live-attenuated vaccines, inactivated formulations pose no risk of reversion to virulence, making them especially critical for immunocompromised individuals, the elderly, and pregnant women. These vaccines are widely used for diseases such as hepatitis A, rabies, polio (IPV), Japanese encephalitis, and influenza, with emerging relevance in pandemic preparedness scenarios.

Their non-replicating nature means booster doses are often required, yet this trade-off is balanced by their ability to induce strong humoral immune responses with well-understood safety parameters. Governments and global health agencies continue to prioritize inactivated vaccines in their procurement strategies, particularly in regions where cold chain stability, regulatory acceptance, and public trust in vaccine safety are high priorities. Moreover, the role of inactivated vaccines in combination formulations-particularly in pediatric immunization schedules-is reinforcing their relevance across global markets.

What Technological Innovations Are Reshaping the Development and Delivery of Inactivated Vaccines?

A wave of innovation is enhancing the scalability, purity, and immunogenicity of inactivated vaccine platforms. Cell culture-based production methods, such as Vero and MDCK cell lines, are replacing traditional egg-based and animal-derived substrates, resulting in safer and more consistent manufacturing. These platforms are particularly useful for producing vaccines against polio, influenza, and rabies. Moreover, novel adjuvants like aluminum salts, MF59, and AS03 are being incorporated to amplify immune responses and reduce the number of required doses.

Another critical advancement is the development of thermostable and lyophilized formulations, which are designed to maintain potency in high-temperature or low-resource settings. This is especially important in rural regions of Africa and Southeast Asia where cold chain logistics are difficult to maintain. In addition, digital tracking systems and smart packaging technologies are being integrated to ensure proper storage, traceability, and usage compliance. These improvements are not only optimizing vaccine logistics but also supporting global mass immunization campaigns, particularly during emergencies like pandemics or sudden disease outbreaks.

Which Disease Targets and Geographies Are Fueling Demand for Inactivated Vaccines?

Demand for inactivated vaccines is particularly strong in pediatric immunization programs and in infectious disease control initiatives across Asia-Pacific, Latin America, and parts of Africa. IPV is increasingly replacing oral polio vaccines as countries move into the final stages of polio eradication, while inactivated rabies vaccines are crucial in managing post-exposure prophylaxis in endemic countries. Seasonal influenza vaccination, which often relies on inactivated quadrivalent formulations, remains a major growth segment in North America and Europe, especially in aging populations and those with chronic diseases.

Emerging infectious threats such as COVID-19 have also reignited global interest in inactivated vaccine platforms. Several COVID-19 vaccines developed using traditional inactivation methods have been deployed at scale in countries like China, India, and the UAE, showcasing the speed and scalability of this platform in crisis response. Additionally, zoonotic threats such as avian influenza and tick-borne encephalitis are further driving the development and deployment of inactivated vaccines for both human and veterinary applications. Public-private partnerships are supporting local manufacturing in lower-income nations, ensuring more equitable access to these vaccines across geographic and economic divides.

The Growth in the Inactivated Vaccines Market Is Driven by Several Factors…

It is driven by the increasing global focus on vaccine safety, particularly for use in vulnerable populations and immunocompromised individuals. Technological advancements in cell culture production and adjuvant development are improving the efficiency, potency, and scalability of inactivated vaccines, making them more suitable for both routine and emergency immunization campaigns. The rising prevalence of zoonotic diseases and emerging pandemics is also accelerating demand for flexible and rapid-response vaccine platforms, in which inactivated vaccines have proven critical.

Additionally, policy shifts such as the transition from OPV to IPV in polio-endemic and transitioning countries are expanding the adoption base of inactivated formulations. Government-supported programs in rabies control, hepatitis A prevention, and pandemic influenza preparedness are further bolstering market growth, supported by Gavi, WHO, and regional health alliances. Increasing uptake of combination pediatric vaccines, including IPV and other inactivated components, is streamlining immunization schedules and improving compliance. The expansion of vaccine manufacturing infrastructure in developing regions, supported by technology transfer and international funding, is helping to reduce production costs and improve global supply security-further fueling the sustained growth of the inactivated vaccines market.

SCOPE OF STUDY:

The report analyzes the Inactivated Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Viral Vaccine Type, Bacterial Vaccine Type); Inactivation Method (Solvent Detergent Method, Radiation Method, pH Concentration, Other Inactivation Methods); Administration Route (Oral, Subcutaneous, Intravenous); End-User (Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • Biological E Limited
  • Boehringer Ingelheim International GmbH
  • CanSino Biologics Inc.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Hualan Biological Engineering Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP33962

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Inactivated Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Emphasis on Routine Immunization Programs Drives Demand for Inactivated Vaccines
    • Increased Preference for Well-Established Vaccine Technologies Supports Market Stability Amid Emerging Threats
    • Global Shift Away From Live Vaccines in Immunocompromised Populations Strengthens Case for Inactivated Platforms
    • Surge in Demand for Safe, Scalable Vaccine Production Platforms Accelerates Adoption of Inactivated Formulations
    • Regulatory Endorsement of Inactivated Vaccines for Pediatric and Elderly Populations Expands Application Scope
    • Growing Public Trust in Inactivated Vaccines Amid Vaccine Hesitancy Supports Uptake in Developed Markets
    • Expansion of Travel Medicine and Pre-Exposure Vaccination Drives Market for Inactivated Viral and Bacterial Vaccines
    • WHO and GAVI Support for Inactivated Vaccine Procurement in LMICs Fuels Global Immunization Equity
    • R&D Investments in Adjuvant Technologies Improve Immunogenicity and Dosing Efficiency of Inactivated Vaccines
    • Use of Inactivated Platforms in Combination and Multivalent Vaccines Enhances Pediatric Coverage and Compliance
    • Rising Demand for Thermostable Vaccine Formulations Boosts Development of Heat-Resistant Inactivated Products
    • Emergence of Pandemic and Outbreak Scenarios Repositions Inactivated Vaccines as Rapid-Response Tools
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Inactivated Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Viral Vaccine Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Viral Vaccine Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Viral Vaccine Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bacterial Vaccine Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bacterial Vaccine Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Bacterial Vaccine Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Homecare Settings End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Homecare Settings End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Homecare Settings End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Solvent Detergent Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Solvent Detergent Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Solvent Detergent Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Radiation Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Radiation Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Radiation Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for pH Concentration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for pH Concentration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for pH Concentration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Inactivation Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Inactivation Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other Inactivation Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • JAPAN
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • CHINA
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • EUROPE
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Inactivated Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • FRANCE
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • GERMANY
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 143: UK Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Inactivated Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • INDIA
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 218: India Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Inactivated Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Inactivated Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
  • AFRICA
    • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!